Autolus Therapeutics plc 8-K

What Happened
Autolus Therapeutics plc announced on April 29, 2026 that its Board approved an operational efficiency plan that includes a reduction in force affecting approximately 13% of the company’s workforce. The company said the actions (some of which began in H2 2025) are expected to be completed by the third quarter of 2026. Autolus estimates total expenses related to the realignment of about $8 million, largely severance and termination-related costs, with a significant portion expected to be recorded in the first half of 2026. The company also confirmed its full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million.

Key Details

• Board-approved plan announced April 29, 2026; implementation expected complete by Q3 2026.
• Workforce reduction: approximately 13% of employees (includes actions begun in H2 2025).
• Estimated restructuring cost: ~$8 million (severance and termination-related); material portion to be recorded in H1 2026.
• Affected employees will be offered separation benefits, including severance and temporary healthcare assistance.
• Company reaffirmed 2026 AUCATZYL net product revenue guidance: $120M–$135M.

Why It Matters
The filing signals management is taking steps to reduce operating expenses through headcount cuts, with a clearly stated near-term cost ($8M) that will impact reported results in 2026 (notably H1). At the same time, Autolus maintained its 2026 revenue outlook for AUCATZYL, so investors can track whether the cost reductions translate into improved margins without affecting product revenue. The company also cautioned that actual costs and timing may differ and that additional unanticipated charges are possible.